Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 43
Filter
Add more filters

Publication year range
1.
Drug Chem Toxicol ; : 1-8, 2024 Aug 19.
Article in English | MEDLINE | ID: mdl-39155655

ABSTRACT

Cannabidiol (CBD) is a major phytocannabinoid from Cannabis sativa. It is currently widely available and widely used in the USA, but despite its rapid progress to market, the pharmacology and toxicology of both CBD and cannabidiol-rich cannabis extracts (CRCE) remain largely unknown. The goals of this study were to investigate the potential of a novel human microphysiological system to emulate CRCE-induced hepatotoxicity and pharmacological properties demonstrated in animal models. For this purpose, C57BL6/J male mice were subjected to dosing with either 0, 61.5, 184.5, or 615 mg/kg of CRCE for 10 days. The liver-on-chip system, incorporating human primary hepatocytes, sinusoidal endothelial cells, as well as Kupffer and stellate cells was subjected to 0, 300, 1,200, or 4,400 ng/mL of CRCE (8 h exposure followed by 16 h washout) for 5 days. Administration of CRCE in mice resulted in nearly 4-fold elevations of plasma ALT at 615 mg/kg (p < 0.01) and a dose-dependent decrease in intrahepatic miR-122. Elevated levels of ALT, paralleled by decreased intrahepatic and increased effluent levels of miR-122, were also observed in the liver-on-chip, although these results were not statistically significant. Exposure to CRCE resulted in a robust and dose-dependent induction of key cytochrome P450 enzymes, namely Cyp1a2, Cyp2b6 (CYP2B10), Cyp2e1, and Cyp2c9 (CYP2C19) in both mouse livers and liver-on-chip. The results of this study demonstrate the congruence between the responses observed in mouse and human liver-on-chip experimental systems and provide evidence of the potential microphysiological systems hold for translating animal data into clinical practice.

2.
Gastroenterology ; 159(6): 2181-2192.e1, 2020 12.
Article in English | MEDLINE | ID: mdl-32841647

ABSTRACT

BACKGROUND & AIMS: Clostridioides difficile toxin A (TcdA) activates the innate immune response. TcdA co-purifies with DNA. Toll-like receptor 9 (TLR9) recognizes bacterial DNA to initiate inflammation. We investigated whether DNA bound to TcdA activates an inflammatory response in murine models of C difficile infection via activation of TLR9. METHODS: We performed studies with human colonocytes and monocytes and macrophages from wild-type and TLR9 knockout mice incubated with TcdA or its antagonist (ODN TTAGGG) or transduced with vectors encoding TLR9 or small-interfering RNAs. Cytokine production was measured with enzyme-linked immunosorbent assay. We studied a transduction domain of TcdA (TcdA57-80), which was predicted by machine learning to have cell-penetrating activity and confirmed by synchrotron small-angle X-ray scattering. Intestines of CD1 mice, C57BL6J mice, and mice that express a form of TLR9 that is not activated by CpG DNA were injected with TcdA, TLR9 antagonist, or both. Enterotoxicity was estimated based on loop weight to length ratios. A TLR9 antagonist was tested in mice infected with C difficile. We incubated human colon explants with an antagonist of TLR9 and measured TcdA-induced production of cytokines. RESULTS: The TcdA57-80 protein transduction domain had membrane remodeling activity that allowed TcdA to enter endosomes. TcdA-bound DNA entered human colonocytes. TLR9 was required for production of cytokines by cultured cells and in human colon explants incubated with TcdA. TLR9 was required in TcdA-induced mice intestinal secretions and in the survival of mice infected by C difficile. Even in a protease-rich environment, in which only fragments of TcdA exist, the TcdA57-80 domain organized DNA into a geometrically ordered structure that activated TLR9. CONCLUSIONS: TcdA from C difficile can bind and organize bacterial DNA to activate TLR9. TcdA and TcdA fragments remodel membranes, which allows them to access endosomes and present bacterial DNA to and activate TLR9. Rather than inactivating the ability of DNA to bind TLR9, TcdA appears to chaperone and organize DNA into an inflammatory, spatially periodic structure.


Subject(s)
Bacterial Toxins/metabolism , Clostridioides difficile/immunology , Clostridium Infections/immunology , Colitis/immunology , Enterotoxins/metabolism , Toll-Like Receptor 9/metabolism , Animals , Anti-Bacterial Agents/adverse effects , Clostridioides difficile/genetics , Clostridioides difficile/metabolism , Clostridium Infections/chemically induced , Clostridium Infections/microbiology , Colitis/chemically induced , Colitis/microbiology , DNA, Bacterial/metabolism , Disease Models, Animal , Female , Gastrointestinal Microbiome/drug effects , Gastrointestinal Microbiome/immunology , Humans , Immunity, Innate , Mice , Mice, Knockout , Molecular Chaperones/metabolism , Signal Transduction/immunology , Toll-Like Receptor 9/genetics
3.
Molecules ; 24(12)2019 Jun 17.
Article in English | MEDLINE | ID: mdl-31212965

ABSTRACT

The goal of this study was to investigate the potential for a cannabidiol-rich cannabis extract (CRCE) to interact with the most common over-the-counter drug and the major known cause of drug-induced liver injury-acetaminophen (APAP)-in aged female CD-1 mice. Gavaging mice with 116 mg/kg of cannabidiol (CBD) [mouse equivalent dose (MED) of 10 mg/kg of CBD] in CRCE delivered with sesame oil for three consecutive days followed by intraperitoneally (i.p.) acetaminophen (APAP) administration (400 mg/kg) on day 4 resulted in overt toxicity with 37.5% mortality. No mortality was observed in mice treated with 290 mg/kg of CBD+APAP (MED of 25 mg/kg of CBD) or APAP alone. Following CRCE/APAP co-administration, microscopic examination revealed a sinusoidal obstruction syndrome-like liver injury-the severity of which correlated with the degree of alterations in physiological and clinical biochemistry end points. Mechanistically, glutathione depletion and oxidative stress were observed between the APAP-only and co-administration groups, but co-administration resulted in much greater activation of c-Jun N-terminal kinase (JNK). Strikingly, these effects were not observed in mice gavaged with 290 mg/kg CBD in CRCE followed by APAP administration. These findings highlight the potential for CBD/drug interactions, and reveal an interesting paradoxical effect of CBD/APAP-induced hepatotoxicity.


Subject(s)
Acetaminophen/adverse effects , Cannabidiol/adverse effects , Hepatic Veno-Occlusive Disease/diagnosis , Hepatic Veno-Occlusive Disease/etiology , Animals , Biomarkers , Cannabidiol/chemistry , Cannabis/chemistry , Chemical and Drug Induced Liver Injury/diagnosis , Chemical and Drug Induced Liver Injury/etiology , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Synergism , Female , Liver/drug effects , Liver/metabolism , Liver/pathology , Mice , Mice, Inbred Strains , Phytochemicals/adverse effects , Phytochemicals/chemistry , Plant Extracts/adverse effects
4.
Adv Anat Pathol ; 25(4): 238-253, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29465420

ABSTRACT

This manuscript presents a review of infectious causes of gastritis aimed at the practicing anatomic pathologist. We shall highlight unique histologic findings and clinical attributes that will assist those analyzing endoscopically obtained mucosal biopsies of the stomach or resection specimens.


Subject(s)
Gastritis/microbiology , Humans
5.
Purinergic Signal ; 14(1): 37-46, 2018 03.
Article in English | MEDLINE | ID: mdl-29134411

ABSTRACT

Ecto-nucleoside triphosphate diphosphohydrolases (E-NTPDases) are cell surface-located transmembrane ecto-enzymes of the CD39 superfamily which regulate inflammation and tissue repair by catalyzing the phosphohydrolysis of extracellular nucleotides and modulating purinergic signaling. In the liver, NTPDase2 is reportedly expressed on portal fibroblasts, but its functional role in regulating tissue regeneration and fibrosis is incompletely understood. Here, we studied the role of NTPDase2 in several models of liver injury using global knockout mice. Liver regeneration and severity of fibrosis were analyzed at different time points after exposure to carbon tetrachloride (CCl4) or 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) or partial hepatectomy in C57BL/6 wild-type and globally NTPDase2-deficient (Entpd2 null) mice. After chronic CCl4 intoxication, Entpd2 null mice exhibit significantly more severe liver fibrosis, as assessed by collagen content and histology. In contrast, deletion of NTPDase2 does not have a substantial effect on biliary-type fibrosis in the setting of DDC feeding. In injured livers, NTPDase2 expression extends from the portal areas to fibrotic septae in pan-lobular (CCl4-induced) liver fibrosis; the same pattern was observed, albeit to a lesser extent in biliary-type (DDC-induced) fibrosis. Liver regeneration after partial hepatectomy is not substantively impaired in global Entpd2 null mice. NTPDase2 protects from liver fibrosis resulting from hepatocellular injury induced by CCl4. In contrast, Entpd2 deletion does not significantly impact fibrosis secondary to DDC injury or liver regeneration after partial hepatectomy. Our observations highlight mechanisms relating to purinergic signaling in the liver and indicate possible therapeutic avenues and new cellular targets to test in the management of hepatic fibrosis.


Subject(s)
Adenosine Triphosphatases/metabolism , Liver Cirrhosis/enzymology , Liver Regeneration/physiology , Animals , Male , Mice , Mice, Inbred C57BL , Mice, Knockout
6.
J Clin Gastroenterol ; 52(5): 444-451, 2018.
Article in English | MEDLINE | ID: mdl-28362682

ABSTRACT

BACKGROUND: Recent genome-wide association studies have identified 2 genetic polymorphisms in association with nonalcoholic fatty liver disease (NAFLD): patatin-like phospholipase domain containing 3 (PNPLA3) and transmembrane 6 superfamily member 2 (TM6SF2), both of which appear to influence the production of very low density lipoprotein (VLDL). The impact of these genetic variations on lipoprotein metabolism in the setting of nonalcoholic steatohepatitis and liver fibrosis are not fully characterized. MATERIALS AND METHODS: We measured comprehensive lipoprotein profiles by nuclear magnetic resonance among 170 serially recruited patients in an NAFLD registry, and determined their relationships with PNPLA3 and TM6SF2 genotypes. RESULTS: In this cohort, 72% patients had at least 1 allele of either PNPLA3 I148M or TM6SF2 E167K, and 30% carried 2 alleles. In multivariate models adjusting for histologic features of nonalcoholic steatohepatitis and liver fibrosis, PNPLA3 I148M is associated with a decrease in VLDL particle size. Both PNPLA3 I148M and TM6SF2 E167K genotypes were associated with increases in the size of low density lipoprotein (LDL) and high density lipoprotein particles, phenotypes considered atheroprotective. When adjusted for both genotypes, NAFLD activity score, in particular the degree of hepatic steatosis was strongly associated with increases in the size of VLDL particles, the concentration of LDL, especially small LDL particles, and a decrease in the size of high density lipoprotein particles, all of which are linked with a proatherogenic phenotype. CONCLUSIONS: PNPLA3 and TM6SF2 are common genetic variants among NAFLD patients and impact lipoprotein profiles in slightly different ways. The interactions between genotypes, hepatic steatosis, and lipoprotein metabolism shed lights on the pathophysiology of NAFLD, and provide opportunities for personalized treatment in the era of emerging NAFLD therapeutics.


Subject(s)
Lipase/genetics , Liver Cirrhosis/genetics , Membrane Proteins/genetics , Non-alcoholic Fatty Liver Disease/genetics , Adult , Aged , Female , Genetic Predisposition to Disease , Genotype , Humans , Lipoproteins, HDL/genetics , Lipoproteins, HDL/metabolism , Lipoproteins, LDL/genetics , Lipoproteins, LDL/metabolism , Lipoproteins, VLDL/genetics , Lipoproteins, VLDL/metabolism , Liver Cirrhosis/pathology , Magnetic Resonance Spectroscopy , Male , Middle Aged , Non-alcoholic Fatty Liver Disease/physiopathology , Polymorphism, Single Nucleotide , Prospective Studies
7.
J Biol Chem ; 291(42): 22207-22217, 2016 Oct 14.
Article in English | MEDLINE | ID: mdl-27573241

ABSTRACT

We recently discovered a structurally novel class of endogenous lipids, branched palmitic acid esters of hydroxy stearic acids (PAHSAs), with beneficial metabolic and anti-inflammatory effects. We tested whether PAHSAs protect against colitis, which is a chronic inflammatory disease driven predominantly by defects in the innate mucosal barrier and adaptive immune system. There is an unmet clinical need for safe and well tolerated oral therapeutics with direct anti-inflammatory effects. Wild-type mice were pretreated orally with vehicle or 5-PAHSA (10 mg/kg) and 9-PAHSA (5 mg/kg) once daily for 3 days, followed by 10 days of either 0% or 2% dextran sulfate sodium water with continued vehicle or PAHSA treatment. The colon was collected for histopathology, gene expression, and flow cytometry. Intestinal crypt fractions were prepared for ex vivo bactericidal assays. Bone marrow-derived dendritic cells pretreated with vehicle or PAHSA and splenic CD4+ T cells from syngeneic mice were co-cultured to assess antigen presentation and T cell activation in response to LPS. PAHSA treatment prevented weight loss, improved colitis scores (stool consistency, hematochezia, and mouse appearance), and augmented intestinal crypt Paneth cell bactericidal potency via a mechanism that may involve GPR120. In vitro, PAHSAs attenuated dendritic cell activation and subsequent T cell proliferation and Th1 polarization. The anti-inflammatory effects of PAHSAs in vivo resulted in reduced colonic T cell activation and pro-inflammatory cytokine and chemokine expression. These anti-inflammatory effects appear to be partially GPR120-dependent. We conclude that PAHSA treatment regulates innate and adaptive immune responses to prevent mucosal damage and protect against colitis. Thus, PAHSAs may be a novel treatment for colitis and related inflammation-driven diseases.


Subject(s)
Adaptive Immunity/immunology , Colitis/drug therapy , Fatty Acids/pharmacology , Immunity, Innate/drug effects , Immunity, Mucosal/drug effects , Paneth Cells/immunology , Th1 Cells/immunology , Animals , Colitis/chemically induced , Colitis/immunology , Colitis/pathology , Dextran Sulfate/adverse effects , Dextran Sulfate/pharmacology , Male , Mice , Paneth Cells/pathology , Receptors, G-Protein-Coupled/immunology , Th1 Cells/pathology
8.
J Gen Intern Med ; 32(4): 486-489, 2017 Apr.
Article in English | MEDLINE | ID: mdl-27798779

ABSTRACT

Aminotransferase elevations have been described in patients with anorexia nervosa. Hypothesized etiologies have included ischemic hepatitis, refeeding-induced transaminitis, and the process of autophagy. Supervised enteral nutrition is the mainstay of treatment for severe anorexia, but an increase in aminotransferase levels after initiation of enteral feeding presents clinicians with a diagnostic dilemma. We present a 31-year-old woman with anorexia nervosa (body mass index [BMI] of 13.5 kg/m2) who experienced a worsening of aminotransferase elevations even after the initiation of enteral feeding. Despite nutritional supplementation, the patient's weight continued to fall for 6 days. Peak aminotransferase concentrations correlated with the patient's lowest weight and improved only after an increase in BMI was eventually achieved. Secondary causes of severe transaminitis were investigated, and after no cause was found, a liver biopsy was performed. Pathology was consistent with liver injury secondary to severe malnutrition rather than from refeeding syndrome. This case highlights malnutrition as an important cause of aminotransferase elevations and underscores the need for judicious early weight restoration in patients with anorexia and abnormal liver chemistry.


Subject(s)
Anorexia Nervosa/enzymology , Anorexia Nervosa/therapy , Enteral Nutrition , Transaminases/blood , Adult , Anorexia Nervosa/complications , Biomarkers/blood , Body Mass Index , Diagnosis, Differential , Enteral Nutrition/adverse effects , Female , Hepatitis/diagnosis , Hepatitis/enzymology , Hepatitis/etiology , Humans , Liver Function Tests , Malnutrition/complications , Malnutrition/enzymology , Refeeding Syndrome/diagnosis
9.
Am J Gastroenterol ; 111(5): 685-90, 2016 05.
Article in English | MEDLINE | ID: mdl-26977756

ABSTRACT

OBJECTIVES: Objective evidence of inflammation has been associated with the risk of relapse in patients with ulcerative colitis (UC) who are in clinical remission. We compared endoscopic and histologic grades for their ability to predict clinical relapse in this patient population. METHODS: Patients with UC in clinical remission were prospectively enrolled into an observational cohort. Baseline endoscopic scores (Mayo) and histological (Geboes) grades and blood markers were collected. All subjects were followed for 12 months and relapse determined using clinical indices. RESULTS: A total of 179 subjects were enrolled into the study and followed for 12 months. Clinical relapse occurred in 23%; 5% were hospitalized, and 2% underwent colectomy. In univariate analysis, the baseline Mayo endoscopy score and the Geboes histology grade were significantly associated with the later development of clinical relapse (P<0.001 for both), but only the histology grade remained significant in a multivariate model (P=0.006). The relative risk of clinical relapse was 3.5 (95% CI 1.9-6.4, P<0.0001) in subjects whose baseline Geboes grade was ≥3.1. The area under the curve was 0.73 for the Geboes histology grade to identify subjects at risk of future clinical relapse. Of the patients in clinical, endoscopic, and histological remission at baseline (n=82), only 7% had a clinical relapse over the subsequent 12 months. CONCLUSIONS: Histology grade has the strongest association with the risk of clinical relapse in patients with UC who are in clinical remission. Consideration should be given to including this end point in evaluating therapy for UC.


Subject(s)
Colitis, Ulcerative/etiology , Colitis, Ulcerative/pathology , Adult , Colitis, Ulcerative/diagnostic imaging , Endoscopy , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Recurrence , Risk Factors , Time Factors
10.
J Autoimmun ; 72: 102-12, 2016 08.
Article in English | MEDLINE | ID: mdl-27210814

ABSTRACT

BACKGROUND & AIMS: T-helper-type 17 (Th17) cells are involved in autoimmune tissue damage. CD39 is an ectonucleotidase that catalyzes extracellular ATP/ADP hydrolysis, culminating in the generation of immunosuppressive adenosine. Functional CD39 expression confers immunosuppressive properties upon immune cells. As the proportion of CD39 lymphocytes is decreased in juvenile autoimmune liver disease (AILD), we have explored whether decreased CD39 expression is present on Th17 cells and whether this phenomenon is associated with heightened effector function and inflammation. METHODS: Thirty-eight patients with juvenile AILD (22 autoimmune hepatitis and 16 autoimmune sclerosing cholangitis), 8 disease controls (DC) and 16 healthy subjects (HS) were studied. Peripheral blood cell phenotype was determined by flow cytometry; ability to suppress by inhibition of cell proliferation/effector cytokine production; ectoenzymatic activity by thin layer chromatography; expression of adenosine receptor, adenosine deaminase (ADA) and phosphodiesterases (PDE) by quantitative real-time PCR or by Western Blot. RESULTS: CD39(+) Th17 (Th17(CD39+)) cells from HS appear activated and contain high frequencies of lymphocytes producing regulatory cytokines. In AILD, however, Th17(CD39+) cells are markedly diminished and fail to generate AMP/adenosine, thereby limiting control of both target cell proliferation and IL-17 production. When compared to HS, Th17 cells from AILD patients also show lower A2A adenosine receptor expression while displaying similar levels of PDE4A, PDE4B and ADA. Only rare Th17(CD39+) cells are observed by liver immunohistochemistry. CONCLUSIONS: Th17(CD39+) cells in juvenile AILD are both quantitatively decreased and qualitatively deficient. Low levels CD39 and A2A expression may contribute to the perpetuation of Th17 cell effector properties and unfettered inflammation in this disease.


Subject(s)
Antigens, CD/immunology , Apyrase/immunology , Cholangitis, Sclerosing/immunology , Hepatitis, Autoimmune/immunology , Th17 Cells/immunology , Adenosine Deaminase/genetics , Adenosine Deaminase/immunology , Adenosine Deaminase/metabolism , Adolescent , Adult , Antigens, CD/metabolism , Apyrase/metabolism , Blotting, Western , Cell Proliferation , Child , Child, Preschool , Female , Flow Cytometry , Gene Expression/immunology , Humans , Immunohistochemistry , Infant , Interleukin-17/immunology , Interleukin-17/metabolism , Male , Phosphoric Diester Hydrolases/genetics , Phosphoric Diester Hydrolases/immunology , Phosphoric Diester Hydrolases/metabolism , Receptor, Adenosine A2A/genetics , Receptor, Adenosine A2A/immunology , Receptor, Adenosine A2A/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Th17 Cells/metabolism , Young Adult
11.
Abdom Imaging ; 40(8): 3274-91, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26306515

ABSTRACT

The purpose of this two-part article is to review the cross-sectional anatomy of the ampulla and periampullary region, to propose novel and optimized MDCT and MRI techniques that allow accurate evaluation of the ampulla of Vater, and to summarize the cross-sectional imaging features of benign and malignant ampullary conditions. In this first part, we will review the normal anatomy of the ampullary region, provide suggestions on how to optimize evaluation of the ampullary region by MDCT and MRI, and review the imaging features of select epithelial neoplasms of the ampulla. Familiarity with the normal ampullary anatomy and the pathologic conditions involving the ampulla, as well as the use of optimized MDCT and MRI techniques, may improve the diagnostic accuracy of radiologists facing ampullary abnormalities.


Subject(s)
Ampulla of Vater/diagnostic imaging , Ampulla of Vater/pathology , Common Bile Duct Diseases/diagnostic imaging , Common Bile Duct Diseases/pathology , Magnetic Resonance Imaging , Tomography, X-Ray Computed , Ampulla of Vater/anatomy & histology , Common Bile Duct Neoplasms/diagnostic imaging , Common Bile Duct Neoplasms/pathology , Humans
12.
Abdom Imaging ; 40(8): 3292-312, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26306516

ABSTRACT

The purpose of this two-part article is to review the cross-sectional imaging features of benign and malignant ampullary conditions with endoscopic and histopathologic correlation and to present the most common pitfalls in the evaluation of the ampulla. In this part, we will review the mesenchymal and secondary neoplasms of the ampulla, a vast array of benign ampullary conditions, causes of bulging papilla, and pitfalls. Familiarity with ampullary pathologic conditions and pitfalls, as well as the use of optimized MDCT and MRI techniques, may improve the diagnostic accuracy of radiologists facing ampullary abnormalities.


Subject(s)
Ampulla of Vater/diagnostic imaging , Ampulla of Vater/pathology , Common Bile Duct Diseases/diagnostic imaging , Common Bile Duct Diseases/pathology , Magnetic Resonance Imaging , Multidetector Computed Tomography , Common Bile Duct Neoplasms/diagnostic imaging , Common Bile Duct Neoplasms/pathology , Diagnosis, Differential , Humans
13.
Abdom Imaging ; 39(3): 482-7, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24463957

ABSTRACT

A 46-year-old woman with an incidentally discovered hepatic mass at the time of echocardiography underwent additional imaging for characterization. Ultrasound demonstrated a 5.3 cm solid hyperechoic mass. Computed tomography and magnetic resonance imaging showed intratumoral fat and nodular foci of progressive enhancement. The patient underwent surgical resection, with the mass demonstrating histopathologic and immunohistochemical features diagnostic of a hepatic mammary-type myofibroblastoma. We present herein the clinical, imaging, and pathologic features in this unique case of hepatic mammary-type myofibroblastoma. Mammary-type myofibroblastoma is a benign spindle cell tumor typically composed of groups of myofibroblasts within bands of hyalinized collagenous stroma. Some tumors also have an adipocytic component. The tumor is nearly exclusively seen in the breast and although extramammary soft tissue locations have been described, to our knowledge, this is the first reported case in the liver or any visceral site. Although rare, radiologists and clinicians should, therefore, be aware of the possibility of a mammary-type myofibroblastoma when a solid, non-encapsulated, fat containing tumor in the liver is encountered.


Subject(s)
Liver Neoplasms/diagnosis , Liver Neoplasms/ultrastructure , Multimodal Imaging/methods , Neoplasms, Muscle Tissue/diagnosis , Neoplasms, Muscle Tissue/ultrastructure , Diagnosis, Differential , Female , Humans , Liver/diagnostic imaging , Liver/pathology , Liver Neoplasms/surgery , Magnetic Resonance Imaging/methods , Mammary Glands, Human/pathology , Middle Aged , Neoplasms, Muscle Tissue/surgery , Tomography, X-Ray Computed/methods , Ultrasonography, Doppler, Color/methods
14.
Food Chem Toxicol ; 192: 114909, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39128689

ABSTRACT

Cannabidiol (CBD) has gained widespread popularity; however, its pharmacological and toxicological profiles in the context of human genetic diversity remain largely unexplored. Here, we investigated the variability in metabolism and toxicity of CBD-rich cannabis extract (CRCE) in genetically diverse mouse models: C57BL/6J, B6C3F1/J, and NZO/HlLtJ strains. Mice received a single dose of CRCE containing 57.9% CBD at dosages of 0, 246, 738, and 2460 mg/kg of CBD. At 24 h after treatment, no appreciable histomorphological changes were detected in the liver. Plasma bilirubin levels increased markedly in all strains at the highest CBD dose. Mice in all treatment groups displayed significant but distinct increases in ALT and AST levels. While B6C3F1/J and NZO/HlLtJ mice had negligible plasma CBD levels at 738 mg/kg, C57BL/6J mice exhibited levels exceeding 7000 ng/mL. At 2460 mg/kg, high CBD concentrations were found in B6C3F1/J and C57BL/6J mice, but markedly lower levels were seen in NZO/HlLtJ mice. Gene expression profiling showed significant increases in Cyp2b10 across all strains but varying responses in Cyp1a1 expression, indicating strain-specific CYP dysregulation. Genetically diverse mice exhibited differential pharmacological and toxicological responses to CRCE, suggesting a high potential for inter-individual variability in the pharmacology and toxicology of CBD in humans.


Subject(s)
Cannabidiol , Cannabis , Mice, Inbred C57BL , Plant Extracts , Animals , Cannabidiol/administration & dosage , Mice , Plant Extracts/administration & dosage , Plant Extracts/pharmacology , Cannabis/chemistry , Male , Liver/drug effects , Liver/metabolism , Species Specificity , Bilirubin/blood
16.
Orbit ; 32(6): 405-8, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23909455

ABSTRACT

PURPOSE: To report a case of dacryocystitis secondary to intranasal cocaine abuse and to review the literature on the effects of cocaine on sinus, nasal and lacrimal structures. METHODS: Case report and literature review. RESULTS: A 33-year-old male presented with unilateral epiphora and discharge, and clinical examination was consistent with dacryocystitis. He had a 2-year history of intranasal cocaine use. Computed tomography revealed extensive bilateral intranasal and sinus destruction, consistent with cocaine abuse. He was treated with antibiotics followed by dacryocystorhinostomy with silicone intubation. He had 2 recurrences of dacryocystitis and underwent one additional lacrimal surgery. CONCLUSIONS: Cocaine abuse and its accompanying intranasal and sinus destruction should be considered when determining the etiology of nasolacrimal obstruction and dacryocystitis. A medical and social history with specific questions about drug abuse may be useful. Computed tomography is helpful in delineating damage to the sinuses, nose and lacrimal system. Management with antibiotics and dacryocystorhinostomy surgery may result in resolution of symptoms.


Subject(s)
Anesthetics, Local/adverse effects , Cocaine-Related Disorders/etiology , Cocaine/adverse effects , Dacryocystitis/chemically induced , Nasolacrimal Duct/drug effects , Administration, Intranasal , Adult , Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Cocaine-Related Disorders/diagnostic imaging , Cocaine-Related Disorders/therapy , Combined Modality Therapy , Dacryocystitis/diagnostic imaging , Dacryocystitis/therapy , Dacryocystorhinostomy , Fluoroquinolones/therapeutic use , Gatifloxacin , Humans , Lacrimal Duct Obstruction/chemically induced , Lacrimal Duct Obstruction/diagnostic imaging , Lacrimal Duct Obstruction/therapy , Male , Nasolacrimal Duct/diagnostic imaging , Tomography, X-Ray Computed
17.
Biomed Pharmacother ; 167: 115489, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37713991

ABSTRACT

BACKGROUND AND AIMS: Clostridioides difficile infection (CDI) induces intense acute inflammatory responses through toxin release. A combination of antibiotic and anti-inflammatory agents is sometimes recommended in severe, non-responsive cases, although clinical trials have been inconclusive, raising concerns about potential complications. This study aims to investigate the effect of budesonide and mesalamine in the treatment of CDI in a murine model, by evaluating the combination of fidaxomicin and these anti-inflammatory drugs. METHOD: C57BL/6 J female mice pretreated with an antimicrobial mixture were challenged with C. difficile VPI 10463 or culture media by gavage. After the challenge, mice received placebo, fidaxomicin alone (20 mg/kg), or fidaxomicin combined with mesalamine (200, 400 mg/kg) or budesonide (0.2, 1, 10 mg/kg) for 5 days. The mice were monitored for 7 days with weight and survival. Colon and cecum tissues were harvested for histological assessment. RESULTS: CDI of mice caused 80% mortality. Fidaxomicin completely protected against CDI in all parameters (weight, survival and pathscores). Mortality rates were up to 90%, 70% in budesonide(10 mg/kg) and mesalamine (400 mg/kg) treatment group, respectively. Budesonide (0.02,0.1 and 1 mg/kg) adjunction to fidaxomicin worsened the disease outcome according to all tested parameters. While mesalamine in combination with fidaxomicin (200, 400 mg/kg) did not lead to any deaths during CDI treatment, it did not provide additional benefits. CONCLUSIONS: Anti-inflammatory drugs including corticosteroid therapy may worsen the incidence and severity of CDI in this mouse model. These studies may have important clinical implications for understanding the role of anti-inflammatory/ corticosteroid therapy in CDI and inflammatory bowel disease management.

18.
Mol Metab ; 77: 101808, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37716594

ABSTRACT

OBJECTIVE: Mitochondrial pyruvate is a critical intermediary metabolite in gluconeogenesis, lipogenesis, and NADH production. As a result, the mitochondrial pyruvate carrier (MPC) complex has emerged as a promising therapeutic target in metabolic diseases. Clinical trials are currently underway. However, recent in vitro data indicate that MPC inhibition diverts glutamine/glutamate away from glutathione synthesis and toward glutaminolysis to compensate for loss of pyruvate oxidation, possibly sensitizing cells to oxidative insult. Here, we explored this in vivo using the clinically relevant acetaminophen (APAP) overdose model of acute liver injury, which is driven by oxidative stress. METHODS: We used pharmacological and genetic approaches to inhibit MPC2 and alanine aminotransferase 2 (ALT2), individually and concomitantly, in mice and cell culture models and determined the effects on APAP hepatotoxicity. RESULTS: We found that MPC inhibition sensitizes the liver to APAP-induced injury in vivo only with concomitant loss of alanine aminotransferase 2 (ALT2). Pharmacological and genetic manipulation of neither MPC2 nor ALT2 alone affected APAP toxicity, but liver-specific double knockout (DKO) significantly worsened APAP-induced liver damage. Further investigation indicated that DKO impaired glutathione synthesis and increased urea cycle flux, consistent with increased glutaminolysis, and these results were reproducible in vitro. Finally, induction of ALT2 and post-treatment with dichloroacetate both reduced APAP-induced liver injury, suggesting new therapeutic avenues. CONCLUSIONS: Increased susceptibility to APAP toxicity requires loss of both the MPC and ALT2 in vivo, indicating that MPC inhibition alone is insufficient to disrupt redox balance. Furthermore, the results from ALT2 induction and dichloroacetate in the APAP model suggest new metabolic approaches to the treatment of liver damage.


Subject(s)
Chemical and Drug Induced Liver Injury , Liver Diseases , Mice , Animals , Antioxidants/metabolism , Antioxidants/pharmacology , Acetaminophen/adverse effects , Acetaminophen/metabolism , Pyruvic Acid/pharmacology , Alanine Transaminase , Oxidative Stress , Oxidation-Reduction , Glutathione/metabolism , Alanine/pharmacology
20.
Eur J Drug Metab Pharmacokinet ; 47(3): 319-330, 2022 May.
Article in English | MEDLINE | ID: mdl-35137360

ABSTRACT

BACKGROUND AND OBJECTIVES: Whole-body radiation exposure has been shown to alter the pharmacokinetics of certain drugs in both animal models and humans, but little is known about the effect of radiation on psychoactive medications. These drugs may have altered pharmacokinetics when administered during or after space travel or therapeutic or accidental radiation exposure, resulting in reduced efficacy or increased toxicity. METHODS: Methamphetamine was used to determine the effects of acutely administered 1, 3, and 6 Gy radiation on drug pharmacokinetics and pharmacodynamics. Male Wistar rats were exposed to 0, 1, 3, or 6 Gy X-ray radiation on day 0. The serum pharmacokinetics of subcutaneously administered 1 mg/kg methamphetamine was determined on day 3. Methamphetamine-induced (1 mg/kg) locomotor activity was measured on day 5. Brain methamphetamine concentrations were determined 2 h after methamphetamine administration (1 mg/kg) on day 6. Renal and hepatic serum biomarkers were assessed on days 3 and 6, with liver histology performed on day 6. RESULTS: While serum half-life and unchanged methamphetamine urine clearance were unaffected by any radiation dose, maximum methamphetamine concentrations and methamphetamine and amphetamine metabolite area under the serum concentration-time curve values from 0 to 300 min were significantly reduced after 6 Gy radiation exposure. Additionally, methamphetamine-induced locomotor activity and the brain to serum methamphetamine concentration ratio were significantly elevated after 6 Gy radiation. CONCLUSIONS: While 1-6 Gy radiation exposure did not affect methamphetamine elimination, 6 Gy exposure had effects on both subcutaneous absorption and brain distribution. These effects should be considered when administering drugs during or after radiation exposure.


Subject(s)
Methamphetamine , Amphetamine/pharmacokinetics , Animals , Half-Life , Liver , Male , Methamphetamine/pharmacokinetics , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL